clinical trial · NCT07619339
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Non-Small Cell Lung CancerTepotinibIvonescimab
brief summary
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
started
May 27, 2026
primary completion
May 1, 2029
completion
May 1, 2029
last updated
Sep 16, 2026
official title
A Pilot Study of Tepotinib + Ivonescimab in Patients With Advanced METex14 Skipping Positive NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol